Key result
Kilohertz frequency alternating current neuromodulation successfully but variably blocked pharmacologically evoked chemo-afferent carotid sinus nerve responses in an anesthetised porcine model.
Why the study?
Carotid body over-activation contributes to metabolic diseases like type 2 diabetes, and suppressing carotid sinus nerve signalling via neuromodulation may offer a therapeutic strategy.
Does kilohertz frequency alternating current (KHFAC) neuromodulation of the carotid sinus nerve block evoked chemo-afferent responses in a porcine model?
Does kilohertz frequency alternating current (KHFAC) neuromodulation of the carotid sinus nerve block evoked chemo-afferent responses in a porcine model?
KHFAC neuromodulation of the carotid sinus nerve is feasible for blocking chemo-afferent responses in a human-sized large animal model, representing a foundational step toward clinical translation for metabolic diseases like type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports KHFAC carotid sinus nerve block feasibility in porcine model; leaves open translation to metabolic disease therapies.
Recent research supports that over-activation of the carotid body plays a key role in metabolic diseases like type 2 diabetes. Supressing carotid body signalling through carotid sinus nerve (CSN) modulation may offer a therapeutic approach for treating such diseases. Here we anatomically and histologically characterised the CSN in the farm pig as a recommended path to translational medicine. We developed an acute in vivo porcine model to assess the application of kilohertz frequency alternating current (KHFAC) to the CSN of evoked chemo-afferent CSN responses. Our results demonstrate the feasibility of this approach in an acute setting, as KHFAC modulation was able to successfully, yet variably, block evoked chemo-afferent responses. The observed variability in blocking response is believed to reflect the complex and diverse anatomy of the porcine CSN, which closely resembles human anatomy, as well as the need for optimisation of electrodes and parameters for a human-sized nerve. Overall, these results demonstrate the feasibility of neuromodulation of the CSN in an anesthetised large animal model, and represent the first steps in driving KHFAC modulation towards clinical translation. Chronic recovery disease models will be required to assess safety and efficacy of this potential therapeutic modality for application in diabetes treatment.
No takes yet. Share an insight, caveat, or question.
Fjordbakk et al. (2019) studied Healthy (animal model for metabolic diseases) (n=9). Kilohertz frequency alternating current (KHFAC) neuromodulation vs. Pre-block (baseline) response was evaluated on Area under the curve (AUC) for NaCN-induced tidal volume (Vt) response (p=0.001). Kilohertz frequency alternating current neuromodulation successfully but variably blocked pharmacologically evoked chemo-afferent carotid sinus nerve responses in an anesthetised porcine model.
Synapse has enriched 10 related papers. Consider them for comparative context: